{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-075345","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2022-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.641712+00:00","generated_at":"2026-06-24T22:26:43.212443+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VTP-300 shows durable HBsAg reductions in chronic hepatitis B; no serious adverse events","bullets":["Updated interim data (n=39) shows VTP-300 as monotherapy or +nivolumab had no treatment-related SAEs; 2 mild transaminitis cases.","In monotherapy, 3 patients with baseline HBsAg <50 IU/mL had 0.7-1.4 log10 declines durable up to 8 months.","Combination group (8 patients) had mean HBsAg reduction >1 log10 at 6 months, persisting to 1.15 log10 at 8 months.","Robust T cell response with marked CD8+ predominance observed; enrollment complete at 55 patients.","Updated interim analysis for all patients at 6-month follow-up expected end of 2022; new trial dosing expected Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-075345","json":"https://secwatch.observer/filing/0001104659-22-075345.json","markdown":"https://secwatch.observer/filing/0001104659-22-075345.md","text":"https://secwatch.observer/filing/0001104659-22-075345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465922075345/0001104659-22-075345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465922075345/tm2219878d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:26:43.212443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}